(Q34593345)

3 August 2017

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma (English)

1 reference

3 August 2017

phase II clinical trial

0 references

bevacizumab

1 reference

inferred from title

hepatocellular carcinoma

1 reference

15

Shahin Rafii

1 reference

3 August 2017

Abby B Siegel

1

1 reference

3 August 2017

Emil I Cohen

2

1 reference

3 August 2017

Allyson Ocean

3

1 reference

3 August 2017

Deborah Lehrer

4

1 reference

3 August 2017

Alec Goldenberg

5

1 reference

3 August 2017

Jennifer J Knox

6

1 reference

3 August 2017

Helen Chen

7

1 reference

3 August 2017

Sean Clark-Garvey

8

1 reference

3 August 2017

Alan Weinberg

9

1 reference

3 August 2017

John Mandeli

10

1 reference

3 August 2017

Paul Christos

11

1 reference

3 August 2017

Madhu Mazumdar

12

1 reference

3 August 2017

Elizabeta Popa

13

1 reference

3 August 2017

Robert S Brown

14

1 reference

3 August 2017

Jonathan D Schwartz

16

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

Journal of Clinical Oncology

3 August 2017

1 reference

3 August 2017

26

1 reference

3 August 2017

2992-2998

1 reference

3 August 2017

18

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Opportunities for targeted therapies in hepatocellular carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Angiogenesis and hepatocellular carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Quantitative analysis of focal masses at MR imaging: a plea for standardization

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3635806

The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update

27 October 2018

1 reference

12 December 2020

Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis

1 reference

12 December 2020

Correlative Study of Angiogenesis and Dynamic Contrast‐Enhanced Magnetic Resonance Imaging Features of Hepatocellular Carcinoma

1 reference

12 December 2020

Rising incidence of hepatocellular carcinoma in the United States

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2007.15.9947

1 reference

3 August 2017

1 reference

3 August 2017

1 reference